BMS-986165 + cyclosporine

BMS-986165 + cyclosporine is an investigational combination of two drugs: - **BMS-986165 (deucravacitinib)** is a selective oral inhibitor of tyrosine kinase 2 (TYK2), developed by Bristol Myers Squibb. It modulates immune signaling pathways involved in inflammatory and autoimmune diseases, such as psoriasis and psoriatic arthritis[4][5][8][10]. - **Cyclosporine** is a calcineurin inhibitor immunosuppressant that inhibits T-cell activation by blocking interleukin-2 transcription. It has been used for decades to treat conditions like severe psoriasis and organ transplant rejection[7]. The combination has been studied in healthy subjects to assess pharmacokinetics, safety, and tolerability; results indicate it was well tolerated with no clinically meaningful drug-drug interaction[1][2][3]. There are no approved indications for the combination; both drugs are individually approved or under investigation for various immune-mediated diseases.

Brand names

Sotyktu

Other names

deucravacitinib + cyclosporine